Cipla Ltd.

Cipla’s wholly owned subsidiary -- Goldencross Pharma (Goldencross) has completed the sale of its entire shareholding in Wellthy Therapeutics (Wellthy) in terms of the definitive agreement executed on March 06, 2024. The consideration received from such sale is Rs 59.71 lakh for the sale of 5,32,121 Compulsorily Convertible Preference Shares (CCPS) and 10 equity shares held in Wellthy.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.